Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 22 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 22 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.